Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATX 101 - APIM Therapeutics

Next Previous
Drug Profile

ATX 101 - APIM Therapeutics

Alternative Names: ATX-101

Latest Information Update: 27 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator APIM Therapeutics; Norwegian university of science and technology
  • Developer APIM Therapeutics; Columbia University
  • Class Antineoplastics; Peptides
  • Mechanism of Action Protein interaction domain and motif inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Leiomyosarcoma; Liposarcoma
  • Phase I/II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I Solid tumours
  • Preclinical Bladder cancer; Cancer; Multiple myeloma

Most Recent Events

  • 30 Nov 2023 Therapim in collaboration with Novotech terminates a Ib/IIa trial in Ovarian cancer (Late-stage disease, Second-line therapy or greater, Combination therapy), Peritoneal cancer (Late-stage disease, Second-line therapy or greater, Combination therapy), and Fallopian tube cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Australia (IV) due to technical reasons (NCT04814875)
  • 10 Nov 2022 Nordic Nanovector completes its phase I trial in Solid tumours (Late stage disaeses) in Australia (IV) (ACTRN12618001070224)
  • 09 Nov 2022 APIM Therapeutics plans to initiate two clinical studies in Ovarian cancer and Glioblastoma in second half of 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top